AbbVie Inc (ABBV)vsBeta Bionics, Inc. Common Stock (BBNX)
ABBV
AbbVie Inc
$211.32
-2.23%
HEALTHCARE · Cap: $360.63B
BBNX
Beta Bionics, Inc. Common Stock
$10.29
+0.88%
HEALTHCARE · Cap: $441.16M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 55380% more annual revenue ($61.16B vs $110.24M). ABBV leads profitability with a 6.9% profit margin vs -60.3%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
BBNX
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
-33.1%
Fair Value
$10.61
Current Price
$10.29
$0.32 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Revenue surging 56.6% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -22.7% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : BBNX
The strongest argument for BBNX centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 56.6% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : BBNX
The primary concerns for BBNX are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while BBNX is a hypergrowth play — different risk/reward profiles.
BBNX is growing revenue faster at 56.6% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 38/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Beta Bionics, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. The company is headquartered in Irvine, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?